Human serum and plasma have different sources of epidermal growth factor

1990 ◽  
Vol 259 (3) ◽  
pp. R545-R548 ◽  
Author(s):  
A. Lev-Ran ◽  
D. L. Hwang ◽  
D. S. Snyder
Keyword(s):  
Bone Marrow ◽  
Platelet Count ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Molecular Mass ◽  
High Performance ◽  
Regression Line ◽  
Bone Marrow Ablation ◽  
Epidermal Growth ◽  
Marrow Ablation

Epidermal growth factor (EGF) was determined by radioimmunoassay in serum, plasma, and urine of 23 patients undergoing ablative therapy followed by bone marrow transplantation. The difference between the serum and plasma values reflected the amount of EGF released from the platelets at the time of blood coagulation. Platelet-derived EGF strongly correlated with platelet count (r + 0.850, P less than 0.0001), and the intercept of the regression line was very close to zero; one platelet contained approximately 2.5 x 10(-18) g EGF. Correspondingly, when the platelet count dropped after bone marrow ablation from 222 +/- 97 to 33 +/- 13 x 10(9)/l, the serum EGF decreased from 603 +/- 222 to 65 +/- 41 pg/ml (P less than 0.0001). Plasma EGF content did not correlate with the platelet count and did not change significantly after bone marrow ablation (before and after the ablation, correspondingly, 290 +/- 80 and 332 +/- 99 pg/ml, P = 0.194). High-performance liquid chromatographic fractionation of serum and plasma showed different molecular mass distribution of EGF-immunoreactive fractions. The main molecular mass components of the plasma EGF did not change after bone marrow ablation. Urine excretion remained unchanged (320 +/- 133 and 314 +/- 173 pmol EGF/mmol creatinine). We conclude that whereas platelets are the source of serum EGF, the origin of plasma EGF is different and the search of its origin is warranted.

Receptors for epidermal growth factor and insulin-like growth factor-I on preimplantation trophoderm of the pig

Development ◽  
1990 ◽  
Vol 110 (1) ◽  
pp. 221-227
Author(s):  
A.N. Corps ◽  
D.R. Brigstock ◽  
C.J. Littlewood ◽  
K.D. Brown
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Molecular Mass ◽  
Cross Linking ◽  
Relative Molecular Mass ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Igf I ◽  
Epidermal Growth ◽  
Growth Factor I

125I-labelled epidermal growth factor (125I-EGF) and 125I-labelled insulin-like growth factor-I (125I-IGF-I) bound to trophoderm cells from pig blastocysts obtained on days 15–19 of pregnancy. Specific binding was detected on freshly isolated cell suspensions and on cells cultured for several days. The binding of 125I-EGF was inhibited by increasing concentrations of EGF, but not by various other growth factors and hormones. Chemical cross-linking of 125I-EGF to its receptors using disuccinimidyl suberate (DSS) revealed a radiolabelled band of relative molecular mass 160,000, similar to that identified as the EGF receptor in other cell types. The binding of 125I-IGF-I was inhibited by both IGF-I and insulin, indicating that the receptors were either type I IGF receptors or insulin receptors. Cross-linking of 125I-IGF-I to serum-free supernatants from trophoderm cultures showed that the cells secreted an IGF-binding protein, giving a complex of relative molecular mass about 45,000. The presence of receptors for EGF and IGF/insulin suggests that these factors could be involved in regulating the growth and development of the early blastocyst.

scholarly journals Rescue of W-associated mast cell defects in W/Wv bone marrow cells by ectopic expression of normal and mutant epidermal growth factor receptors

Blood ◽  
1993 ◽  
Vol 82 (5) ◽  
pp. 1463-1470
Author(s):  
T von Ruden ◽  
L Stingl ◽  
A Ullrich ◽  
EF Wagner
Keyword(s):  
Signal Transduction ◽  
Bone Marrow ◽  
Mast Cell ◽  
Growth Factor ◽  
Mast Cells ◽  
Epidermal Growth Factor ◽  
Bone Marrow Cells ◽  
Ectopic Expression ◽  
Tissue Type ◽  
Epidermal Growth

Abstract The normal human epidermal growth factor receptor (EGF-R) (HERc), a chimeric EGF-R/v-erbB (HERerbB) receptor, and the ligand-independent oncogenic EGF-R variant (v-erbB) were used to correct the mast cell defects in W/Wv bone marrow (BM) cells. In culture, all three receptor molecules transduced functional mitogenic signals in infected interleukin-3 (IL-3)-dependent bone marrow-derived mast cells (BMMCs) and enabled their differentiation into safranin-positive mast cells resembling connective tissue-type mast cells (CTMCs). Furthermore, expression of these receptors restored the capacity of W/Wv BMMCs to colonize the peritoneal cavity of mast cell-deficient W/Wv mice where they differentiated to safranin-positive cells with similar frequencies as wild-type BMMCs. These experiments show that expression of normal and mutant EGF-Rs in W/Wv BM cells is able to complement the function of the c-kit-encoded Steel factor receptor (SLF-R) in mast cell development. We conclude that signal transduction by normal and mutant EGF-Rs in murine hematopoietic cells apparently involves components also used by the SLF-R, which suggests that these receptors use overlapping pathways for signal transduction.

scholarly journals Transforming growth factor-alpha (TGF-alpha) in human bone marrow: demonstration of TGF-alpha in erythroblasts and eosinophilic precursor cells and of epidermal growth factor receptors in blastlike cells of myelomonocytic origin

Blood ◽  
1995 ◽  
Vol 85 (9) ◽  
pp. 2385-2392 ◽  
Author(s):  
TM Walz ◽  
C Malm ◽  
BK Nishikawa ◽  
A Wasteson
Keyword(s):  
Monoclonal Antibody ◽  
Bone Marrow ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Egf Receptor ◽  
Transforming Growth Factor ◽  
Precursor Cells ◽  
Transforming Growth Factor Alpha ◽  
Epidermal Growth ◽  
Factor Alpha

The expression of transforming growth factor-alpha (TGF-alpha) in human differentiating leukemic cell lines and in circulating human eosinophils prompted the search for an analogous function in normal human bone marrow (BM) cells. Immunohistochemistry, using a monoclonal antibody directed to the mature form of the TGF-alpha molecule, showed TGF-alpha on the erythroblasts of normal donors. This novel property of erythroid cells was found on cells at all stages of maturation, most clearly on nucleated forms but to some extent also on erythrocytes within the BM. The presence of membrane-bound TGF-alpha on erythroblasts was confirmed by immunomagnetic cell sorting with polyclonal TGF-alpha antibodies; the recovered cells consisted almost entirely of erythroblasts. Using another monoclonal antibody directed to TGF-alpha, immunohistochemistry showed a different pattern of positive cells including eosinophilic precursor cells, in accordance with earlier findings in blood eosinophils. In addition, the TGF-alpha immunoreactivity was shown in promyelocytes and neutrophilic myelocytes. The presence of epidermal growth factor (EGF) receptor mRNA in BM cells was demonstrated by reverse transcription polymerase chain reaction, whereas EGF receptor-carrying cells were recognized by immunohistochemistry, using polyclonal antibodies directed to the cytoplasmic part of the EGF receptor. The EGF receptor-positive cell constituted about 3% of the nucleated BM cell population. It was classified as a blastlike cell of myelomonocytic origin by morphologic criteria and CD68 positivity. Our results may indicate a novel function of TGF-alpha in erythrocytic differentiation.

Epidermal growth factor prohormone is secreted in human urine

1992 ◽  
Vol 263 (1) ◽  
pp. E142-E150 ◽  
Author(s):  
J. Lakshmanan ◽  
E. C. Salido ◽  
R. Lam ◽  
D. A. Fisher
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Molecular Mass ◽  
Human Urine ◽  
Age Groups ◽  
Adult Males ◽  
Rat Urine ◽  
Immunoreactive Protein ◽  
Amino Terminal ◽  
Epidermal Growth

Examination of adult human urine by immunoblot analysis with antiserum specific to human recombinant 6-kDa epidermal growth factor (EGF) reveals the presence of an immunoreactive protein with a molecular mass of 165 kDa. This protein is consistently found in the morning (first) but not in day urine of adult males and females. Day urine contains variable proportions of four other high-molecular-weight EGFs with approximate molecular masses of 97, 66, 50, and 42 kDa. The 165-kDa EGF immunoreactive protein reacts with mouse amino-terminal EGF prohormone (proEGF) antiserum and comigrates with mouse urinary proEGF, suggesting that the protein is the human EGF prohormone. The 165-kDa human proEGF exhibits strong binding affinity to concanavalin A, indicating that it is glycosylated. Immunoblotting of urine in infants and children of various age groups demonstrates the presence of proEGF in all age groups, but its concentration is highest in children 2-4 yr of age. These findings, taken together with secretion of proEGF of similar molecular mass in mouse and rat urine, suggest that renal proEGF secretion is an evolutionarily conserved phenomenon and may have an important function or functions distal to the site of its synthesis.

scholarly journals The Effect of Human Bone Marrow Mesenchymal Stem Cells on Epidermal Growth Factor and Epidermal Growth Factor Receptor Expression in Re-epithelialization Process in the Healing of Burns on Experimental Rats

2020 ◽  
Vol 8 (A) ◽  
pp. 508-511
Author(s):  
Gusti Revilla ◽  
Henny Mulyani
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Human Bone ◽  
Human Bone Marrow ◽  
Egfr Expression ◽  
Marrow Mesenchymal Stem Cells ◽  
Epidermal Growth

BACKGROUND: Research on human bone marrow mesenchymal stem cells (hBM-MSCs) for burns healing has been known to increase the percentage of integrin expression of α2β1, type I collagen, transforming growth factor-β, and matrix metalloproteinases-9, but research on giving hBM-MSCs to growth factor expression in the process of re-epithelialization of burn healing has not been done. AIM: This study aims to the effect of hBM-MSCs given on the expression of epidermal growth factor (EGF) and EGF receptor (EGFR) in the process re-epithelialization in the healing of burn experimental rat. MATERIALS AND METHODS: This research is experimental with the post-test only control design, using 30 Wistar rats. Rats were divided into two groups, namely, control (phosphate-buffered saline), and the treatment was given hBM-MSCs, and stem cells were given subcutaneous doses of 2 × 106 cells/ml. Before being treated rats were anesthetized using xylazine and ketamine then the rats were burned in the dorsal (spine) with full-thickness. On the 3, 7, and 14 days, skin tissue was taken to see the expression of EGF and EGFR by immunohistochemical methods. This study was approved by the Ethics Commission of the Faculty of Medicine, Andalas University, Padang. The results of the study were analyzed by the t-test. RESULTS: Immunohistochemical examination of EGF and EGFR expressions after hBM-MSCs administration has significantly increased epithelialization compared with controls. Increased EGF expression was found on days 3 and 7 with moderate positive internal revenue service (IRS) assessment and on day 14 strong positive EGF expression, as well as EGFR expression on days 3 and 7 with moderate positive IRS assessment and on day 14 robust positive EGFR expression. CONCLUSION: This study concluded that giving of hBM-MSCs can increase the expression of EGF and EGFR which enhances the process of re-epithelialization thereby accelerating the healing of burns of experimental rats.

Sign in / Sign up

Export Citation Format

Share Document